Table of Contents

Gene Therapy Program

The Gene Therapy Program (GTP) is a research and development organization within the University of Pennsylvania's Perelman School of Medicine. It is focused on the development and commercialization of gene therapy and associated technologies.

Organization

GTP is partnered with the Orphan Disease Center (ODC) and Penn Center for Innovation (PCI).1)

Personnel

Gene Therapy Program - Team2)
Name Position Notes
James Wilson Director Orphan Disease Center, Perelman School of Medicine, iECURE, Whitehead Institute, Health through Fitness in Orphan Diseases
Antony Appleyard Executive Director, Regulatory Affairs Diamond Pharma Services, Novacta Biosystems, Royal Society of Chemistry, The Organisation for Professionals in Regulatory Affairs (TOPRA)
Fabian Chen Chief Medical Officer Rocket Pharmaceuticals, Novartis, Merck, University of California Los Angeles
Jenny Greig Senior Research Director, Translational Research American Society for Gene and Cell Therapy
Juliette Hordeaux Senior Research Director, Translational Research -
Lori Kellam Senior Director, Research Portfolio Management Temple University
Mike LaBruto Executive Director, Quality Assurance GlaxoSmithKline, Temple University School of Pharmacy
Thomas Logan Chief Strategy and Business Officer BTG
Monique Molloy Chief Administrative Officer Orphan Disease Center (ODC)
William Singleton Executive Director, Program for Comparative Medicine Animal Care Training Services (ACTS)
Simin Zaidi Chief Technology Officer Catalent Biologics
1)
Our Mission & History. University of Pennsylvania Gene Therapy Program. Retrieved May 22, 2023, from https://web.archive.org/web/20230522003917/https://gtp.med.upenn.edu/about/our-mission-history
2)
Our Team. University of Pennsylvania Gene Therapy Program. Retrieved May 22, 2023, from http://archive.today/2023.05.22-003614/https://gtp.med.upenn.edu/about/our-team